Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Results Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC d

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Background: Most BRCA1 or BRCA2 mutation carriers have inherited a single (heterozygous) mutation. Transheterozygotes (TH) who have inherited deleterious mutations in both BRCA1 and BRCA2 are rare, and the consequences of transheterozygosity are poorly understood. Methods: From 32,295 female BRCA1/2 mutation carriers, we identified 93 TH (0.3 %). "Cases" were defined as TH, and "controls" were single mutations at BRCA1 (SH1) or BRCA2 (SH2). Matched SH1 "controls" carried a BRCA1 mutation found in the TH "case". Matched SH2 "controls" carried a BRCA2 mutation found in the TH "case". After matching the TH carriers with SH1 or SH2, 91 TH were matched to 9316 SH1, and 89 TH were matched to 3370 SH2. Results: The majority of TH (45.2 %) involved the three common Jewish mutations. TH were more likely than SH1 and SH2 women to have been ever diagnosed with breast cancer (BC; p = 0.002). TH were more likely to be diagnosed with ovarian cancer (OC) than SH2 (p = 0.017), but not SH1. Age at BC diagnosis was the same in TH vs. SH1 (p = 0.231), but was on average 4.5 years younger in TH than in SH2 (p < 0.001). BC in TH was more likely to be estrogen receptor (ER) positive (p = 0.010) or progesterone receptor (PR) positive (p = 0.013) than in SH1, but less likely to be ER positive (p < 0.001) or PR positive (p = 0.012) than SH2. Among 15 tumors from TH patients, there was no clear pattern of loss of heterozygosity (LOH) for BRCA1 or BRCA2 in either BC or OC. Conclusions: Our observations suggest that clinical TH phenotypes resemble SH1. However, TH breast tumor marker characteristics are phenotypically intermediate to SH1 and SH2

Assessing associations between the AURKAHMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers

While interplay between BRCA1 and AURKA-RHAMM-TPX2-TUBG1 regulates mammary epithelial polarization, common genetic variation in HMMR (gene product RHAMM) may be associated with risk of breast cancer in BRCA1 mutation carriers. Following on these observations, we further assessed the link between the AURKA-HMMR-TPX2-TUBG1 functional module and risk of breast cancer in BRCA1 or BRCA2 mutation carriers. Forty-one single nucleotide polymorphisms (SNPs) were genotyped in 15,252 BRCA1 and 8,211 BRCA2 mutation carriers and subsequently analyzed using a retrospective likelihood appr

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10-8, HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10-8, HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4×10-8, HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific associat

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

Introduction: More than 70 common alleles are known to be involved in breast cancer (BC) susceptibility, and several exhibit significant heterogeneity in their associations with different BC subtypes. Although there are differences in the association patterns between BRCA1 and BRCA2 mutation carriers and the general population for several loci, no study has comprehensively evaluated the associations of all known BC susceptibility alleles with risk of BC subtypes in BRCA1 and BRCA2 carriers. Methods: We used data from 15,252 BRCA1 and 8,211 BRCA2 carriers to analyze the associations between approximately 200,000 genetic variants on the iCOGS array and risk of BC subtypes defined by estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and triple-negative- (TN) status; morphologic subtypes; histological grade; and nodal involvement. Results: The estimated BC hazard ratios (HRs) for the 74 known BC alleles in BRCA1 carriers exhibited moderate correlations with the corresponding odds ratios from the general population. However, their associations with ER-positive BC in BRCA1 carriers were more consistent with the ER-positive as

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify 13 candidate causal SNPs associated with serous OC (P=9.2 × 10-20), ER-negative BC (P=1.1 × 10-13), BRCA1-associated BC (P=7.7 × 10-16) and triple negative BC (P-diff=2 × 10-5). Genotype-gene expression associations are identified for candidate target genes ANKLE1 (P=2 × 10-3) and ABHD8 (P<2 × 10-3). Chromosome conformation capture identifies interactions between four candidate SNPs and ABHD8, and luciferase assays indicate six risk alleles increased transactivation of the ADHD8 promoter. Targeted deletion of a region containing risk SNP rs56069439 in a putative enhancer induces ANKLE1 downregulation; and mRNA stability assays indicate functional effects for an ANKLE1 3′-UTR SNP. Altogether, these data suggest that multiple SNPs at 19p13 regulate ABHD8 and perhaps ANKLE1 expression, and indicate common mechanisms underlying breast and ovarian cancer risk

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

Background: Full-term pregnancy (FTP) is associated with a reduced breast cancer (BC) risk over time, but women are at increased BC risk in the immediate years following an FTP. No large prospective studies, however, have examined whether the number and timing of pregnancies are associated with BC risk for BRCA1 and BRCA2 mutation carriers. Methods: Using weighted and time-varying Cox proportional hazards models, we investigated whether reproductive events are associated with BC risk for mutation carriers using a retrospective cohort (5707 BRCA1 and 3525 BRCA2 mutation carriers) and a prospective cohort (2276 BRCA1 and 1610 BRCA2 mutation carriers), separately for each cohort and the combined prospective and retrospective cohort. Results: For BRCA1 mutation carriers, there was no overall association with parity compared with nulliparity (combined hazard ratio [HRc] ¼ 0.99, 95% confidence interval [CI] ¼ 0.83 to 1.18). Relative to being uniparous, an increased number of FTPs was associated with decreased BC risk (HRc¼ 0.79, 95% CI ¼ 0.69 to 0.91; HRc¼ 0.70, 95% CI ¼ 0.59 to 0.82; HRc¼ 0.50, 95% CI ¼ 0.40 to 0.63, for 2, 3, and 4 FTPs, respectively, Ptrend < .0001) and increasing duration of breastfeeding was associated with decreased BC risk (combined cohort Ptrend ¼ .0003). Relative to being nulliparous, uniparous BRCA1 mutation carriers were at increased BC risk in the prospective analysis (prospective hazard ration [HRp] ¼ 1.69, 95% CI ¼ 1.09 to 2.62). For BRCA2 mutation carriers, being parous was associated with a 30% increase in BC risk (HRc ¼ 1.33, 95% CI ¼ 1.05 to 1.69), and there was no apparent decrease in risk associated with multiparity except for having at least 4 FTPs vs. 1 FTP (HRc¼ 0.72, 95% CI ¼ 0.54 to 0.98). Conclusions: These findings suggest differential associations with parity between BRCA1 and BRCA2 mutation carriers with higher risk for uniparous BRCA1 carriers and parous BRCA2 carriers

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers

Quercetin Diminishes The Binding Of Hemoglobin To The Red Blood Cell Membrane

Hemoglobin (Hb) oxidation leads to the formation of hemichrome, which binds to the membrane and causes red blood cell removal by the reticuloendothelial system. In the present investigation, the effect of flavonoids on Hb oxidation and their binding to red blood cell (RBC) membranes were studied using tert-butyl hydroperoxide (tert-BOOH) to promote oxidative stress. The intrinsic antioxidant activity of RBC was able to prevent the binding of Hb to the membrane at tert-BOOH concentrations up to 0.4 mM. At higher concentrations, a brown pellet was observed and represented the appearance of membrane-bound oxidized Hb. Oxidations performed in membrane-free Hb solutions with an identical oxidative system showed less Hb oxidation. These observations suggest that erythrocyte membrane lipid peroxidation enhances the oxidative damage of Hb, increasing its binding to membranes. Quercetin partially protected Hb against oxidation by tert-BOOH and reduced the levels of the membrane bound hemichrome. Lipid peroxidation was also significantly suppressed by quercetin. Rutin and morin had little effect in preventing Hb binding to RBC membranes, indicating the importance of structure in the antioxidant properties of flavonoids. In the absence of oxidant, the peroxidation of erythrocyte membrane and isotonic hemolysis were protected by quercetin. These results suggest that quercetin displays a beneficial role on aging of RBC.415563Luna, E.J., Kidd, G.H., Branton, D., Identification by peptide analysis of the spectrin-binding protein in human erythrocytes (1979) J Biol Chem, 254, pp. 2526-2532Hargreaves, W., Giedd, K.N., Verkleij, A., Reassociation of ankyrin with band 3 in erythrocyte membranes and in lipid vesicles (1980) J Biol Chem, 255, pp. 11965-11972Bennett, V., Stenbuck, P.J., The membrane attachment protein for spectrin is associated with band 3 in human erythrocyte membrane (1979) Nature, 280, pp. 468-473Bennett, V., Stenbuck, P.J., Association between ankyrin and the cytoplasmic domain of band 3 isolated from the human erythrocyte membrane (1980) J Biol Chem, 255, pp. 6424-6432Shaklai, N., Yguerabide, J., Ranney, H.M., Classification and localization of hemoglobin binding sites on the red blood cell membrane (1977) Biochemistry, 16, pp. 5585-5592Salhany, J.M., Cordes, K.A., Gaines, E.D., Light-scattering measurements of hemoglobin binding to the erythrocyte membrane. Evidence for transmembrane effects related to a disulfonic stilbene binding to band 3 (1980) Biochemistry, 19, pp. 1447-1454Waugh, S.M., Low, P.S., Hemichrome binding to band 3: Nucleation of Heinz bodies on the erythrocyte membrane (1985) Biochemistry, 24, pp. 34-39Kiefer, C.R., Trainor, J.F., McKenney, J.B., Hemoglobin-spectrin complexes: Interference with spectrin tetramer assembly as a mechanism for compartmentalization of band 1 and band 2 complexes (1995) Blood, 86, pp. 366-371Bates, D., Winterbourn, C.C., Haemoglobin denaturation, lipid peroxidation and haemolysis in phenylhydrazine-induced anaemia (1984) Biochim Biophys Acta, 798, pp. 84-87Snyder, L.M., Fortier, N.L., Trainor, J., Effect of hydrogen peroxide exposure on normal human erythrocyte deformability, morphology, surface characteristics, and spectrin-hemoglobin cross-linking (1985) J Clin Invest, 76, pp. 1971-1977Fortier, N., Snyder, L.M., Garver, F., The relationship between in vivo generated hemoglobin skeletal protein complex and increased red cell membrane rigidity (1988) Blood, 71, pp. 1427-1431Itano, H.A., Hirota, K., Vedvick, T.S., Ligands and oxidants in ferrihemichrome formation and oxidative hemolysis (1977) Proc Natl Acad Sci USA, 74, pp. 2556-2560French, J.K., Winterboum, C.C., Carrell, R.W., Mechanism of oxyhaemoglobin breakdown on reaction with acetylphenylhydrazine (1978) Biochem J, 173, pp. 19-26Trotta, R.J., Sullivan, S.G., Stern, A., Lipid peroxidation and hemoglobin degradation in red blood cells exposed to t-butyl hydroperoxide. Dependence on glucose metabolism and hemoglobin status (1981) Biochim Biophys Acta, 678, pp. 230-237Van Der Zee, J., Van Steveninck, J., Koster, J.F., Inhibition of enzymes and oxidative damage of red blood cells induced by t-butylhydroxperoxide-derived radicals (1989) Biochim Biophys Acta, 980, pp. 175-180Slater, T., Free radical mechanisms in tissue injury (1984) Biochem J, 222, pp. 1-15Pryor, W., Oxy-radicals and related species: Their formation, lifetimes, and reactions (1986) Annu Rev Physiol, 48, pp. 657-667Yagi, K., Lipid peroxidation and human diseases (1987) Chem Phys Lipids, 45, pp. 337-351Hollman, P.C.H., Katan, M.B., Absorption, metabolism and health effects of dietary flavonoids in man (1997) Biomed Pharmacother, 51, pp. 305-310Van Aker, F.A.A., Schouten, O., Haenen, G.R.M.M., Flavonoids can replace α-tocopherol as an antioxidant (2000) FEBS Lett, 473, pp. 145-148Bors, W., Michel, C., Saran, M., Flavonoid antioxidants: Rate constants for reactions with oxygen radicals (1994) Methods Enzymol, 234, pp. 420-429Jovanovic, S.V., Steenken, S., Tosic, M., Flavonoids as antioxidants (1994) J Am Chem Soc, 116, pp. 4846-4851Ratty, A.K., Das, N.P., Effects of flavonoids on nonenzymatic lipid peroxidation: Structure-activity relationship (1988) Biochem Med Metab Biol, 39, pp. 69-79Laughton, M.J., Evans, P.J., Moroney, M.A., Inhibition of mammalian 5-lipooxygenase and cyclooxygenase by flavonoids and phenolic dietary additives. Relationship to antioxidant activity and to iron ion-reducing ability (1991) Biochem Pharmacol, 42, pp. 1673-1681Decharneux, T., Dubois, F., Beauloye, C., Effect of various flavonoids on lysosomes subjected to an oxidative or an osmotic stress (1992) Biochem Pharmacol, 44, pp. 1243-1248Korkina, L.G., Afanas'ev, I.B., Antioxidant and chelating properties of flavonoids (1997) Adv Pharmacol, 38, pp. 151-163Afanas'ev, I.B., Dorozhko, A.I., Brodskii, A.V., Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation (1989) Biochem Pharmacol, 38, pp. 1763-1769Saija, A., Scalese, M., Lanza, M., Flavonoids as antioxidant agents: Importance of their interaction with biomembranes (1995) Free Radic Biol Med, 19, pp. 481-486Ferrali, M., Signorini, C., Caciotti, B., Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity (1997) FEBS Lett, 416, pp. 123-129Winterbourn, C.C., Oxidative reactions of hemoglobin (1990) Methods Enzymol, 186, pp. 265-272Stocks, J., Normandy, T.L., The autoxidation of human red cell lipids induced by hydrogen peroxide (1971) Br J Haematol, 20, pp. 95-111Stern, A., Red cell oxidative damage (1985) Oxidative Stress, pp. 75-90. , Sies H, ed. London: Academic PressPeisach, J., Blumberg, W.E., Rachmilewitz, E.A., The demonstration of ferrihemichrome intermediates in Heinz body formation following the reduction of oxyhemoglobin A by acetylphenylhydrazine (1975) Biochim Biophys Acta, 393, pp. 404-418Minetti, M., Mallozzi, C., Scorza, G., Role of oxygen and carbon radicals in hemoglobin oxidation (1993) Arch Biochem Biophys, 302, pp. 233-244Skaper, S.D., Fabris, M., Ferrari, V., Quercetin protects cutaneous tissue-associated cell types including sensory neurons from oxidative stress induced by glutathione depletion: Cooperative effects of ascorbic acid (1997) Free Radic Biol Med, 22, pp. 669-678Cao, G., Sofic, E., Prior, R.L., Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationship (1997) Free Radic Biol Med, 22, pp. 749-760Hebbel, R.P., Eaton, J.W., Balasingam, M., Spontaneous oxygen radical generation by sickle erythrocytes (1982) J Clin Invest, 70, pp. 1253-1259Saija, A., Scalese, M., Lanza, M., Flavonoids as antioxidant agents: Importance of their interaction with biomembranes (1995) Free Radic Biol Med, 19, pp. 481-486Boyer, R.F., Clark, H.M., La Roche, A.P., Reduction and release of ferritin iron by plant phenolics (1988) J Inorg Biochem, 32, pp. 171-181Uri, N., (1961) Antoxidation and Antioxidants, pp. 133-169. , London: LundbergErben-Russ, M., Michel, C., Bors, W., Absolute rate constant of alkoxyl radical reactions in aqueous solution (1987) J Phys Chem, 91, pp. 2362-2365Jain, S.K., Hochstein, P., Polymerization of membrane components in aging red blood cells (1980) Biochem Biophys Res Commun, 92, pp. 247-254Barclay, L.R.C., Locke, S.J., MacNeil, J.M., Autoxidation of micelles and model membranes - Quantitative kinetic measuurements can be made by using either water or lipid-soluble initiators with water-soluble or lipid-soluble chain-breaking antioxidants (1984) J Am Chem Soc, 106, pp. 2479-2481Grinberg, L.N., Rachmilewitz, E.A., Newmark, H., Protective effects of rutin against hemoglobin oxidation (1994) Biochem Pharmacol, 48, pp. 643-649Hollman, P.C.H., Van Der Gaag, M., Mengelers, M.J.B., Absorption and disposition kinetics of the dietary antioxidant quercetin in man (1996) Free Radic Biol Med, 21, pp. 703-70